> Titan Pharmaceuticals announced it was launching a Phase III trial for opioid independence but discontinued a Phase II trial of an experimental therapy for CHF without explanation. Report [1]
> South San Francisco-based Poniard has secured a $15 million loan. Release [2]
> Bilcare has acquired DHP, a UK-based clinical trials service provider. Report [3]
> Insert Therapeutics has completed a $10 million private placement. Release [4]
> Evolutec has raised 2.8 million stg in a private placement. Report [5]
> Millennium Pharmaceuticals discussed plans to focus on Velcade and pipeline development in its latest quarterly report. Report [6]
> The FDA has signed off on Human Genome Sciences Phase III trial of LymphoStat-B. Report [7]
And Finally... Researchers are studying the use of fat stem cells for breast reconstruction. Release [8]
Links:
[1] http://www.bizjournals.com/sanfrancisco/stories/2006/10/23/daily28.html
[2] http://biz.yahoo.com/prnews/061026/sfth058.html?.v=74
[3] http://www.expresspharmaonline.com/20061031/market06.shtml
[4] http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20061026005352&newsLang=en
[5] http://www.lse.co.uk/FinanceNews.asp?shareprice=&ArticleRef=82227&ArticleHeadline=Evolutec_raises_28_mln_stg_in_placing_at_118p
[6] http://www.thestreet.com/_googlen/newsanalysis/biotech/10317735.html?cm_ven=GOOGLEN&cm_cat=FREE&cm_ite=NA
[7] http://www.streetinsider.com/FDA/Human+Genome+Sciences+(HGSI)+Gets+FDA+Okay+for+Phase+3+LymphoStat-B+Study/1287721.html
[8] http://www.eurekalert.org/pub_releases/2006-10/uopm-fsc102606.php